FDA Moves to Strengthen Postmarketing Rx Safety

Ken Rankin
Published Online: Saturday, January 1, 2005

Shaken by the discovery of serious safety problems with Vioxx and a number of antidepressant drugs approved for marketing in the United States, the FDA announced a series of new steps designed to identify risks associated with prescription medicines currently on the nation's pharmacy shelves.

The measures include a new FDA-sponsored study by the Institute of Medicine to examine the effectiveness of the nation's new drug approval system, and a series of workshops and Advisory Committee meetings that will explore "emerging concerns" about medications already on the market.

The FDA also plans to implement a new program for adjudicating differences of professional opinion concerning possible safety risks posed by approved drugs. Because these scientific "disagreements can have a potentially significant public health impact," the new system will employ an independent "ad hoc panel" of experts to review and resolve disputes, a representative from the agency said.

Latest Articles
Patients with asthma can now access Spiriva Respimat with a prescription at pharmacies across the country.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Latest Issues